Jessica Sorrentino

Jessica Sorrentino

Company: Istari Oncology

Job title: Senior Director Translational Medicine


PVSRIPO, a Novel Intratumoral Viral Immunotherapy, Generates a Robust Immune Response in the Tumor Microenvironment to Yield Systemic Anti-Tumor Efficacy 11:15 am

PVSRIPO is a genetically modified type 1 oral poliovirus (PV) vaccine and engages CD155 (PV receptor and the ligand for TIGIT) on malignant cells and antigen-presenting cells (APC) in the tumor microenvironment (TME) Preclinically, PVSRIPO has demonstrated oncolytic activity in multiple tumor types, and a unique non-lethal infection of APCs leads to substantial innate immune…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.